We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Vascular Disease Plasma Marker Confirmed in Diabetes Patients

By LabMedica International staff writers
Posted on 02 Feb 2016
Print article
Image: Carotid Intima-Media Thickness (CIMT) ultrasound exam showing a carotid artery with a wall that is much thicker than normal and mild plaque formation (Photo courtesy of Preventive Cardiology Consultants).
Image: Carotid Intima-Media Thickness (CIMT) ultrasound exam showing a carotid artery with a wall that is much thicker than normal and mild plaque formation (Photo courtesy of Preventive Cardiology Consultants).
Pre-kallikrein (PK) has previously been suggested as a marker for diabetic vascular disease of the kidneys, but a new study supports the idea that increased plasma PK levels are an independent risk factor for whole-body diabetic vascular disease, similar to the risks of high triglycerides or high blood pressure in heart disease.

The types of blood vessel malfunction seen in patients with diabetes causes the cells of the intima-media to spread to the surface, allowing PK to contact them directly and this contact closes the circuit of an alternative pathway of chronic inflammation. Scientists who study the kallikrein-kinin system suspect that this chronic inflammation is responsible for the blood vessel thickening observed in diabetic kidney disease, retinopathy, and atherosclerosis.

Scientists at the Medical University of South Carolina (Charleston, SC, USA) and their colleagues enrolled participants in Epidemiology of Diabetes Interventions and Complications (EDIC), a multicenter longitudinal observational study of the development of macrovascular complications and further progression of microvascular complications. The study was conducted on a subset of 636 subjects from the Diabetes Control and Complications Trial DCCT/EDIC cohort.

Plasma PK was activated with ∼0.4 nmol/L Hageman factor fragment (betaFXIIa), and the formed plasma kallikrein was detected by hydrolysis of the chromogenic substrate H-D-Pro-Phe-Arg-paranitroanilide (DiaPharma; Franklin, OH, USA) according to the published procedure, and was expressed as units per milliliter (U/mL). Factor XII:coagulant and high molecular weight kininogen (HK):coagulant, plasma concentrations of fibrinogen and plasminogen activator inhibitor (PAI-1) activity levels were also determined. Carotid intima-media thickness was measured by B-mode ultrasonography.

The circulating levels of plasma PK were measured in 636 type 1 diabetic subjects from plasma collected in years 1997–1999. The PK levels were symmetrically distributed and ranged from 0.2-3.0 U/mL, with a mean value of 1.29 U/mL. A positive and significant association was found between PK levels and body mass index (BMI), and with HbA1c, a marker of metabolic control. They also found that patients with higher levels of PK in their blood have thicker layers of intima-media in the vasculature of their carotids.

Ayad A. Jaffa, PhD, the senior author of the study said, “These preclinical studies not only will give us insights into the involvement of plasma PK in vascular disease, but will also contribute to development of novel treatment strategies for diabetic vascular disease.” The study was published ahead of print on November 24, 2015, in the journal Diabetes.

Related Links:

Medical University of South Carolina 
DiaPharma 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.